Литература

1. Антохин E.Ю., Дробижев М.Ю., Калинина Е.В., Сорокина Е.Ю. Практика применения антипсихотиков и корректоров в психиатрии. Первые результаты программы АНКОРПСИ (антипсихотики и корректоры в психиатрии). Социальная и клиническая психиатрия. 2015. Т. 25, № 2. С. 91–94.
2. Голенков А.В. Основы психиатрии: синдромы и психотропные средства. Чебоксары: Изд-во Чуваш. ун-та, 2019. 104 с.
3. Голенков А.В., Сафронов С.А., Кузнецов С.Д. Результаты однодневной переписи больных с психическими расстройствами в трех психиатрических больницах Чувашии // Социальная и клиническая психиатрия. 2015. Т. 25, № 3. C. 56–60.
4. Горбенко Л.Н., Дъяченко С.В., Кортелев В.В., Слободенюк Е.В. Анализ структуры фармацевтического рынка нейролептиков в госпитальном секторе на примере города Хабаровска // Дальневосточный медицинский журнал. 2013. Т. 1. C. 91–94.
5. Гурович И.Я., Шмуклер А.Б., Костюк Г.П., Нарышкин А.В. Контингент пациентов психиатрической больницы (по материалам однодневной переписи) // Социальная и клиническая психиатрия. Т. 23, № 2. С. 5–14.
6. Касерес М.С., Пенас-Ледо Е.М., Рубиа А., Лерена А. Повышение использования антипсихотиков второго поколения в первичном звене медицинской помощи: возможная взаимосвязь с числом госпитализаций пациентов с шизофренией // Социальная и клиническая психиатрия. T. 19, № 1. С. 56–60.
7. Петров В.И. Фармакоэпидемиология и фармакоэкономика – новые направления доказательной медицины // Вестник Волгоградского государственного медицинского университета. 2005. № 4(16). С. 3–7.
8. Препараты лидеры Российского фармацевтического рынка в 2016 году // Ремедиум. № 3. C. 118–150.
9. Рациональная фармакотерапия в психиатрической практике: руководство для практикующих врачей / под общ. ред. Ю.А. Александровского, Н.Г. Незнанова. М.: Литтерра, 2014. 1080 с.
10. Шацберг А.Ф., Дебаттиста Ч. Руководство по клинической психофармакологии / под общ. ред. А.Б. Смулевича, С.В. Иванова. 2-е изд., перераб. и доп. М.: МЕДпресс-информ, 2017. 656 с.
11. Adams C.E., Fenton M., Quraishi S., David A.S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. J. Psychiatry, 2001, vol. 179, pp. 290–299.
12. Ahn J., McCombs J.S., Jung C., Croudace T.J., McDonnell D., Ascher-Svanum H., Edgell E.T., Shi L. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health, 2008, vol. 11(1), pp. 48–56. DOI: 10.1111/j.1524-4733.2007.00214.x.
13. Alexopoulos G.S., Streim J., Carpenter D., Docherty J.P. Using antipsychotic agents in older patients. Clin. Psychiatry, 2004, vol. 65, Suppl. 2, pp. 5–99.
14. Asensio C., Escoda N., Sabaté M., Carbonell P., López P., Laporte J.R. Prevalence of use of antipsychotic drugs in the elderly in Catalonia. J. Clin. Pharmacol., 2018, vol. 74(9), pp. 1185–1186. DOI: 10.1007/s00228-018-2469-6.
15. Bachmann C.J., Aagaard L., Bernardo M., Brandt L. et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr. Scand., 2017, vol. 136(1), pp. 37–51. DOI: 10.1111/acps.12742.
16. Bachmann C.J., Lempp T., Glaeske G., Hoffmann F. Antipsychotic Prescription in Children and Adolescents (An Analysis of Data from a German Statutory Health Insurance Company from 2005 to 2012). Deutsches Ärzteblatt Int., 2014, vol. 111(3), pp. 25–34. DOI: 10.3238/arztebl.2014.0025.
17. Bo Q.J., Li X.B., Wang Z.M., Li A.N., Ma X., Wang C.Y. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study. Clin. Psychopharmac, 2016, vol. 36, no. 2, pp. 125–129.
18. Bonnot O., Dufresne M., Herrera P., Michaud E., Pivette J., Chaslerie A., Sauvaget A., Vigneau C. Influence of socioeconomic status on antipsychotic prescriptions among youth in France. BMC Psychiatry, 2017, vol. 8, pp. 17–82. DOI: 10.1186/s12888-017-1232-1233.
19. Brett J., Karanges E.A., Daniels B., Buckley N.A., Schneider C., Nassir A., Zoega H., McLachlan A.J., Pearson S.A. Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. NZJ Psychiatry, 2017, vol. 51(10), pp. 990–999. DOI: 10.1177/0004867417721018.
20. Brett J., Daniels B., Karanges E.A., Buckley N.A., Schneider C., Nassir A., McLachlan A.J., Pearson S. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. J. Clin. Pharmacol., 2017, vol. 83(11), pp. 2581–2588. DOI: 10.1111/bcp.13369.
21. Bristow G.C., Bostrom J.A., Haroutunian V., Sodhi M.S. Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophr Res., 2015, vol. 167(1–3), pp. 57–63. DOI: 10.1016/j.schres.2015.01.025.
22. Castle D., Morgan V., Jablensky A. Antipsychotic use in Australia: the patients’ perspective. N Z J Psychiatry, 2002, vol. 36(5), pp. 633–641. DOI: 10.1046/j.1440-1614.2002.01037.x.
23. Citrome L., Jaffe A., Levine J. Data points: depot antipsychotic use in New York State hospitals, 1994 to 2009. Serv., 2010, vol. 61(1), p. 9. DOI: 10.1176/appi.ps.61.1.9.
24. Davis K. Use and Expenses for Prescribed Psychotherapeutics, by Subclass, 2009: Estimates for the U.S. Civilian Noninstitutionalized Population. Statistical Brief #386. September 2012. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.meps.ahrq.gov/mepsweb/ data_files/publications/st386/stat386.shtml.
25. Dong M., Zeng L.N., Zhang Q., Yang S.Y., Chen L.Y. et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey. Asian J. Psychiatr., 2019, vol. 45, pp. 74–80. DOI: 10.1016/j.ajp.2019.08.010.
26. Edwards N.C., Locklear J.C., Rupnow M.F., Diamond R.J. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics, 2005, vol. Suppl 1, pp. 75–89. DOI: 10.2165/00019053-200523001-00007.
27. García del Pozo J., Isusi Lomas L., Carvajal García-Pando A., Martín Rodríguez I., Sáinz Gil M., García del Pozo V., Velasco Martín A. Evolution of antipsychotic drug consumption in the autonomous community of Castile and Leon, Spain (1990–2001). Esp. Salud Publica, 2003, vol. 77(6), pp. 725–733.
28. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta­regression analysis. Med. J., 2000, vol. 321, pp. 1371–1376. DOI: 10.1136/bmj.321.7273.1371.
29. Hálfdánarson Ó., Zoëga H., Aagaard L., Bernardo M., Brandt L. et al. International trends in antipsychotic use: A study in 16 countries, 2005–2014. Neuropsychopharmacol., 2017, vol. 27, no. 10, pp. 1064–1076. DOI: 10.1016/ j.euronewo.2017.07.001.
30. Herriot P., Kheirani K.. Survey of depot antipsychotic prescribing in southern Adelaide. Australas Psychiatry, 2005, vol. 13(3), pp. 253–257. DOI: 1080/j.1440-1665.2005.02196.x.
31. Hollingworth S.A., Siskind D.J., Nissen L.M., Robinson M., Hall W.D. Patterns of antipsychotic medication use in Australia 2002–2007. NZJ Psychiatry, 2010, vol. 44(4), pp. 372–377. DOI: 10.3109/00048670903489890.
32. Højlund M., Pottegård A., Johnsen E., Kroken R.A., Reutfors J., Munk-Jørgensen P., Correll C.U. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. J. Clin. Pharmacol., 2019, vol. 28, pp. 1598–1606. DOI: 10.1111/bcp.13945.
33. Kalverdijk L.J., Bachmann C.J., Aagaard L., Burcu M., Glaeske G. et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012. Child Adolesc. Psychiatry Ment. Health, 2017, vol.11. no. 55, pp. 1–9. DOI: 10.1186/s13034-017-0192-1.
34. Kane J.M., Leucht S., Carpenter D., Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Clin. Psychiatry, 2003, vol. 64, suppl 12, pp. 5–19.
35. Kaye J.A., Bradbury B.D., Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. J. Clin. Pharmacol., 2003, vol. 56(5), pp. 569–575. DOI: 10.1046/j.1365-2125.2003.01905.x.
36. Kelly M., Dornan T., Pringsheim T. The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians. CMAJ Open., 2018, vol.30, no. 6(2), pp. E191–E196. DOI: 10.9778/cmajo.20170145.
37. Lao K.S.J., Tam A.W.Y, Wong I.C.K., Besag F.M.C., Man K.K.C., Chui C.S.L., Chan E.W. Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups. Drug Saf., 2017, vol. 26(11), pp. 1387–1394. DOI: 10.1002/pds.4244.
38. Lehmkuhl G., Schubert I. Psychotropic Medication in Children and Adolescents. Deutsches Ärzteblatt Int., 2014, vol. 111(3), pp. 23–24. DOI: 3238/arztebl.2014.0023.
39. Marston L., Nazareth I., Petersen I., Walters K., Osborn D.P. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open., 2014, vol. 4(12), e006135. DOI: 10.1136/bmjopen-2014-006135.
40. Meyers B.S., Jeste D.V. Geriatric psychopharmacology: evolution of a discipline. Clin. Psychiatry, 2010, vol. 71(11), pp. 1416–1424. DOI: 10.4088/JCP.10r06485gry.
41. Mond J., Morice R., Owen C., Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. NZJ. Psychiatry, 2003, vol. 37(1), pp. 55–61. DOI: 10.1046/j.1440-1614.2003.01110.x.
42. Montastruc F., Bénard-Laribière A., Noize P., Pambrun E., Diaz-Bazin F., Tournier M., Bégaud B., Pariente A. Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. J. Clin. Pharmacol., 2018, vol. 74(5), pp. 619–626. DOI: 10.1007/s00228-017-2406-0.
43. Olfson M., Blanco C., Liu S.M., Wang S., Correll C.U. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Gen. Psychiatry, 2012, vol. 69(12), pp. 1247–1256. DOI: 10.1001/archgenpsychiatry.2012.647.
44. Read J., Williams J. Positive and Negative Effects of Antipsychotic Medication: An International Online Survey of 832 Recipients. Drug Saf., 2019, vol. 14(3), pp. 173–181. DOI: 10.2174/ 1574886314666190301152734.
45. Sankaranarayanan J., Puumala S.E. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996–2003: national estimates and associated factors. Clin Ther., 2007, vol. 29(4), pp. 723–741. DOI: 1016/j.clinthera.2007.04.017.
46. Sankaranarayanan J., Puumala S.E. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004. Med. Res. Opin., 2007, vol. 23(6), pp. 1375–1385. DOI: 10.1185/030079907X187900.
47. Santamaría B., Pérez M., Montero D., Madurga M., de Abajo F.J. Use of antipsychotic agents in Spain through 1985–2000. Psychiatry, 2002, vol. 17(8), pp. 471–476. DOI: 10.1016/s0924-9338(02)00705-8
48. Sim K., Su A., Ungvari G.S., Fujii S., Yang S.Y., Chong M.Y., Si T., Chung E.K., Tsang H.Y., Chan Y.H., Shinfuku N., Tan C.H. Depot antipsychotic use in schizophrenia: an East Asian perspective. Psychopharmacol., 2004, vol.19(2), pp. 103–109. DOI: 10.1002/hup.571.
49. Stagnitti M.N. Trends in Antipsychotics Purchases and Expenses for the U.S. Civilian Noninstitutionalized Population, 1997 and 2007. Statistical Brief #275. January 2010. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://meps.ahrq.gov/mepsweb/ data_files/ publications/st275/stat275.pdf.
50. Stephenson C.P., Karanges E., McGregor I.S. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. NZJ. Psychiatry, 2013, vol. 47(1), pp. 74–87. DOI: 10.1177/0004867412466595.
51. Svensson S.A., Hedenrud T.M., Wallerstedt S.M. Attitudes and behaviour towards psychotropic drug prescribing in Swedish primary care: a questionnaire study. BMC Fam. Pract., 2019, vol. 20(1): 4. DOI: 10.1186/s12875-018-0885-4.
52. Trifirò G., Spina E., Brignoli O., Sessa E., Caputi A.P., Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999–2002. J. Clin. Pharmacol, 2005, vol. 61(1), pp. 47–53. DOI: 10.1007/s00228-004-0868-3.
53. Westaway K. Sluggett J.K., Alderman C., Procter N., Roughead E. Prevalence of multiple antipsychotic use and associated adverse effects in Australians with mental illness. J. Evid. Based Healthc, 2016, vol. 14(3), pp. 104–112. DOI: 10.1097/XEB.0000000000000082.
54. Wheeler A. Atypical antipsychotic use for adult outpatients in New Zealand’s Auckland and Northland regions. NZ Med. J., 2006, vol. 119(1237): U2055.
55. Wilkinson S., Mulder R.Т. Antipsychotic prescribing in New Zealand between 2008 and 2015. NZ Med. J., 2018, vol. 131, no. 1485, pp. 52–59.
56. Wysowski D.K., Baum C. Antipsychotic drug use in the United States, 1976–1985. Gen. Psychiatry, 1989, vol. 46(10), pp. 929–932.
57. Xiang Y.T., Wang C.Y., Si T.M., Lee E.H., Ungvari G.S., Chiu H.F., Yang S.Y., Chong M.Y., Tan C.H., Kua E.H.,Fujii S., Sim K., Yong M.K., Trivedi J.K., Chung E.K., Udomratn P., Chee K.Y., Sartorius N., Shinfuku N. Use of Anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry, 2011, pp. 114–118. DOI: 10.1055/s-0031-1275658.
58. Yang S.Y., Chen L.Y., Najoan E., Kallivayalil R.A., Viboonma K, Jamaluddin R. et al. Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry Clin. Neurosci., 2018, vol. 72(8), pp. 572–579. DOI: 10.1111/pcn.12676.